OncoMatch/Clinical Trials/NCT03587844
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Is NCT03587844 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including brentuximab vedotin and brentuximab vedotin for mycosis fungoides.
Treatment: brentuximab vedotin · brentuximab vedotin · brentuximab vedotin — The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: CD30 negative
Disease stage
Required: Stage IB OR HIGHER
disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: brentuximab vedotin (brentuximab vedotin)
Exception: Cohort 2 patients eligible if previously treated; Cohort 1 patients excluded if previously treated
For Cohort 1, patients who have not received brentuximab vedotin are eligible. For Cohort 2, patients who have previously had brentuximab vedotin for MF/SS are eligible. Patients previously treated on Cohort 1 who were discontinued due to toxicity are not eligible for Cohort 2. Previous use of brentuximab vedotin (for Cohort 1 ONLY). For Cohort 2, patients who previously progressed on the standard 1.8mg/kg dose and schedule of brentuximab vedotin are ineligible.
Cannot have received: systemic anti-cancer therapy
Exception: must be discontinued at least 2 weeks prior to treatment
Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment.
Cannot have received: systemic therapy for another primary malignancy (other than T-cell lymphoma)
Exception: adjuvant or maintenance therapy for other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK Principal Investigator
Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma). Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK Principal Investigator.
Lab requirements
Kidney function
No severe renal impairment (CrCL <30 mL/min)
Liver function
No moderate or severe hepatic impairment (Child-Pugh B or C)
Severe renal impairment (CrCL <30 mL/min) [excluded]. Moderate or severe hepatic impairment (Child-Pugh B or Child-Pugh C) [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University Medical Center · Stanford, California
- Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth · Middletown, New Jersey
- Memorial Sloan Kettering Bergen · Montvale, New Jersey
- Memorial Sloan Kettering Commack · Commack, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03587844 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior brentuximab vedotin, systemic anti-cancer therapy, systemic therapy for another primary malignancy (other than T-cell lymphoma) disqualifies patients from enrollment.
What disease stage is eligible?
Stage IB OR HIGHER is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages